FDA authorizes sale of Zyn nicotine pouches, saying public health benefits outweigh risk
Zyn and the retailers who sell the product have run afoul of regulators in recent years. The FDA in April of last year warned 119 retailers to stop selling Zyn to underage people, and the company was ordered to pay $1.2 million last year for violating Washington, D.C.’s smokeless tobacco ban.
Altria Group stock outperformed the S&P 500 over the past year (total return), something you don't hear about so often. See ...
Officials proposed limiting the amount of nicotine to make cigarettes less addictive, but it's unclear if the incoming ...
Despite the seemingly restrictive nature of the FDA's proposed ruling, I remain highly optimistic about the resilience and ...
U.S. regulators are proposing to cap the amount of nicotine in cigarettes at non-addictive levels, in a potential world-first ...
Discover why Altria may be a strong investment opportunity, with potential for significant total returns and a possible ...
In a report released today, Eric Serotta from Morgan Stanley maintained a Hold rating on Altria Group (MO – Research Report), with a price ...
Dividing the $500 by $4.08 equals about 123 shares, assuming the board of directors pays the same dividend rate. If Altria ...
Hosted on MSN2d
Altria Group Earnings Preview: What to ExpectAltria Group, Inc. (MO), headquartered in Richmond, Virginia, is a leading producer and seller of smokeable and oral tobacco ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback